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Alzheimer’s disease (AD) is the most common form of dementia that aﬀects several million people worldwide. The major
neuropathological hallmarks of AD are the presence of extracellular amyloid plaques that are composed of Aβ40 and Aβ42 and
intracellular neuroﬁbrillary tangles (NFT), which is composed of hyperphosphorylated protein Tau. While the amyloid plaques
and NFT could deﬁne the disease progression involving neuronal loss and dysfunction, signiﬁcant cognitive decline occurs before
their appearance. Although signiﬁcant advances in neuroimaging techniques provide the structure and physiology of brain of AD
cases, the biomarker studies based on cerebrospinal ﬂuid (CSF) and plasma represent the most direct and convenient means to
study the disease progression. Biomarkers are useful in detecting the preclinical as well as symptomatic stages of AD. In this paper,
we discuss the recent advancements of various biomarkers with particular emphasis on CSF biomarkers for monitoring the early
development of AD before signiﬁcant cognitive dysfunction.
1.Introduction
Alzheimer’s disease (AD) is the most widespread neu-
rodegenerative disease globally [1] and is estimated to
aﬄict more than 27 million people worldwide [2]. AD
accounts for at least 60% of all dementia diagnosed clinically.
The major pathological hallmarks of AD are the loss of
neurons, occurrence of extracellular senile plaques as well
as intracellular neuroﬁbrillary tangles (NFT) [3]. Senile
plaques are primarily composed of amyloid β-protein (Aβ),
which is produced from the amyloid precursor protein
(APP) by sequential proteolytic cleavages made by two pro-
teolytic enzymes, β-secretase (β-site APP-cleaving enzyme;
BACE) and γ-secretase (Figure 1)[ 4]. Amyloid plaque is
an aggregate of Aβ containing 40–42/43 residues. NFT
is primarily composed of hyperphosphorylated form of
Tau protein [5]. Tau is synthesized within the neuron
and localized in the axon where it promotes stability and
assembly of microtubules [6]. During AD progression, tau
is hyperphosphorylated and subsequently dissociated from
microtubule and polymerized into paired helical ﬁlaments
(Figure 1)[ 5, 6]. Although the clinical symptoms of AD are
frequently diagnosed in older age, the degenerative process
probably starts many years before the clinical onset of the
disease [7, 8]. Currently, the diagnosis and treatment of AD
is limited. The presymptomatic detection of AD is crucial, as
it would facilitate the development of an eﬃcient and rapid
treatment of this destructive disorder early on (for recent
review see [9–11]).
The biomarkers are the entities whose concentration,
presence,andactivityareassociatedwithdisease.Biomarkers
are essential part of disease treatments as they are essential
for diagnosis, monitoring the disease progression, detecting
earlyonsetofthedisease,monitoringtheeﬀectoftherapeutic
intervention, and also avoiding false diagnosis of the disease
[19]. An ideal biomarker (1) should be highly speciﬁc, (2)
shouldpredictthecourseofillnessaccurately,and(3)should
reﬂect the degree of response to treatment. The biomarker
research for AD has signiﬁcantly advanced in recent years
(Table 1)[ 9, 10]. The neuroimaging techniques assess the
regional structure and function of the brain, as well as assist
identifying the biochemical proﬁle of brain dysfunction.
The body ﬂuids such as cerebrospinal ﬂuid (CSF), plasma,
and urine are considered as important sources for the
AD biomarker development (Table 1). CSF is considered a
better source for biomarker development as it is in direct
contact with the extracellular space of the brain and can
reﬂect biochemical changes that occur inside the brain.2 International Journal of Alzheimer’s Disease
Table 1: Some promising biomarkers in diagnosis of AD.
Category Markers Advantages Limitations References
Imaging
(1) Noninvasive (1) Expensive
[12–14] CT, PET, PIB-PET, (2) Provides structural and functional (2) Requires experienced personnel
MRI details of brain immediately (3) The sensitivity and speciﬁcity to
(3) Can reveal disease progression AD is not satisfactory
Plasma
α2-Macroglobulin, (1) Noninvasive (1) Less correlation to AD
[15–17] Complement (2) Samples are easily accessible (2) Less sensitive and speciﬁc for AD
factor H, Aβ42 diagnosis (due to epitope masking)
CSF
Aβ42, t-tau, (1) Can correlate AD directly (1) Invasive, sample has to be collected
[10, 18] p-tau p-tau/Aβ42, (2) Highly sensitive and speciﬁc by lumbar puncture
t-tau/Aβ42 (3) Can detect AD progression (2) Irreproducible diagnosis due to
sample storage and transportation
β-APP
β-secretase
γ-secretase
Membrane
A β42 and other
truncated isoforms
Disregulation of
kinase activity
Aβ42 Oligomers
Amyloid plaques
Oxidative
stress
Microtubule
disintegration
Hyperphosphorylated tau
NFT
Tau bound
to microtubule Axonal injury
t-tau
P
P
P
P
P
P
P
P
P
P
P
P
Figure 1: Pathological cascades and potential biomarkers of AD. Proteolytic cleavage of APP ﬁrst by β-secretase followed by γ-secretase can
produce Aβ42 and other shorter Aβ fragments. The subsequent aggregation of Aβ42 results in oligomers and amyloid ﬁbrils. Amyloid
ﬁbrils are eventually deposited as senile plaques as shown. The toxicity of oligomers and amyloid ﬁbrils could lead to the cascade of
tau-hyperphosphorylation, which is otherwise bound to microtubules, providing microtubule stability. Upon hyperphosphorylation, tau
dissociates from microtubules and aggregates into NFT, which could eventually cause increased cytoskeleton ﬂexibility and neuronal death.
Thus far, three CSF biomarkers, Aβ42, total-tau (t-tau),
and phosphorylated-tau (p-tau), have been found to have
the highest diagnostic potential. Biomarkers of inﬂamma-
tion and oxidative stress and urine-based biomarkers are
among the other sources that provide vital information on
development and progression of AD. Unfortunately, none
of the biomarkers presently available are able to accomplish
the disease diagnosis single-handedly. Monitoring more than
one biomarker at the same time is suggested to be suitable
for detecting the disease progression. The main focus of
this paper is to provide insights on the various potential
biomarkers with particular emphasis on CSF biomarkers for
AD diagnosis. These biomarkers are very promising for early
diagnosis of AD.International Journal of Alzheimer’s Disease 3
2. ImagingBiomarkers
Neuroimaging techniques provide structural and functional
details of the brain immediately [20, 21]. The imaging
techniques are also helpful to predict and monitor the
disease progression. Recent progress of functional and
molecular neuroimaging [22] could provide insights into
brain structure and physiology and also could detect the
speciﬁc proteins and protein aggregates due to AD in the
brain [20].
The loss of brain volume is one of the consequences of
AD neurodegeneration [11, 21], and it could be diﬀerenti-
ated from normal brain by using computerized tomography
(CT) and magnetic resonance imaging (MRI) techniques
[23]. These techniques are able to show neuronal loss,
atrophy of medial temporal regions, as well as neuroﬁbrillary
tangles in the brain of AD patients. Using MRI technique,
it is now possible to distinguish atrophy during early stage
of AD from the atrophy of normal aging [24]. MRI has
also the ability to distinguish AD subjects from normal
controls, with a very high sensitivity and speciﬁcity [24].
MRI can reveal disease progression from cognitive normalcy
to mild cognitive impairment (MCI) and to AD [12].
DiscriminationofADfromotherformsofdementia,namely,
frontotemporal dementia (FTD) and DLB (dementia with
Lewy bodies) is also possible based on diﬀerent atrophy
patterns that MRI reveals [25–27]. AD is also associated with
metabolic impairment with typical regional pattern in the
brain and could be detected by positron emission tomog-
raphy (PET). If 18F-2-deoxy-2-ﬂuoro-D-glucose (FDG) is
chosen for PET, the concentrations of tracer imaged then
gives tissue metabolic activity, in terms of regional glucose
uptake. PET-FDG has been employed to examine regional
cerebral metabolism, which is helpful in distinguishing AD
from normal patients [13, 28–30]. Recently, several other
radiologically contrast compounds have been developed for
PET imaging, which could bind the pathological structures
such as amyloid plaques, NFT, activated microglia, and
reactive astrocytes, enabling the examination of antemortem
pathological changes due to AD. The compounds that have
been reported as probes for amyloid plaques in PET imag-
ing include, [18F] FDDNP (2-(1-{6-[(2-[F-18] ﬂuoroethyl)
(methyl) amino]-2-naphthyl} ethylidene) malononitrile),
18F-BAY94-9172, 11C-SB-13, 11C-BF-227, and 11C-PIB.
The only compound developed that can bind NFT in vivo
is [18F] FDDNP. The 11C-PIB (PIB, Pittsburgh compound
B) has been the most extensively studied and applied in AD
research[14,31].InindividualswithAD,increasedretention
of PIB shows a very speciﬁc pattern that is restricted to brain
regions (frontal, parietal, temporal, occipital cortices, and
striatum), typically associated with amyloid deposition [32].
A signiﬁcant number of cognitively normal individuals over
the age of 60 show a PIB signal pattern indistinguishable
from that of individuals with AD, suggesting that mea-
surement of PIB using PET can detect a preclinical stage
of the disease. When PIB-PET was performed along with
the Aβ42 concentrations in CSF of AD patients, the PIB-
positive group showed low Aβ42 levels in the cerebrospinal
ﬂuid [33–35]. This ﬁnding is consistent with the “amyloid
sink” hypothesis [36, 37], according to which the soluble
Aβ42 is retained in the brain once plaques are formed.
Besides the radiological studies of amyloid plaques and NFT,
the PET imaging agent which images the inﬂammation
due to activated microglia and reactive astrocytes has been
developed. For example, increased expression of peripheral
benzodiazepine receptor (PBR) has been target for the com-
pound [11C] (R)-PK11195. The study using this compound
in conjunction with PIB has suggested that microgliosis
occurs concomitantly with amyloid deposition and may have
direct role in cognitive dysfunction [38]. Like microglia,
the changes in astrocytes on association with plaques could
be used as biomarkers. For example, using inhibitors of
monoamine oxidase B as radiotracers in AD has targeted
the elevation of monoamine oxidase B activity [39, 40].
Although all of these imaging techniques are helpful for
diagnosis of AD, the approach faced overlapping symptoms
due to other pathological processes and normal aging. The
approach also needs expensive instruments and experienced
personnel for its application in routine diagnosis of AD.
Fluid Biomarkers. The sampling of CSF and plasma repre-
sents the most direct and convenient means to study the
biochemical changes occurring in the central nervous system
[10, 19, 41]. These ﬂuids are the most attractive resources
for ongoing research for discovering AD biomarkers. Most
of the research has been performed either with the plasma or
CSF, yet CSF represents more suitable source for biomarker
discovery.
3.Plasma Biomarkers
Plasma is the liquid portion of blood where red blood
cells, white blood cells, and platelets are suspended. Plasma
could be easily isolated from whole blood by low speed
centrifugation in the presence of an anticoagulant. The
easier sampling of blood plasma makes this ﬂuid ideal for
biomarker investigation. However, plasma biomarkers as
reliable markers for AD have met little success (Table 1).
Various blood biomarkers have been proposed, yet changes
in the levels of these molecules have proved diﬃcult to verify
in independent studies. Multiple studies have identiﬁed
plasma proteins whose expression levels in AD patients diﬀer
from controls. For example, α2-Macroglobulin (α2M) and
complementfactorH(CFH)showedanincreasedexpression
inADsubjectsthanincontrol[15].Bothoftheseproteinsare
shown to be present in senile plaques [42, 43]. Similarly, the
increased levels of α1-antitrypsin [44], α1-antichymotrypsin
[45, 46], and decreased levels of Apolipoprotein A1 [47]i n
bloodplasma/serumwereobservedinADpatientscompared
to healthy controls. Although these proteins may reﬂect
pathological processes observed in AD and could diﬀeren-
tiate diseased plasma compared to controls, these diﬀerences
haveyettoachievesensitivity,speciﬁcity,andreproducibility.
Irreproducibility might occur due to diﬀerent analytical
methodologies utilized in various laboratories, diﬀerent
choice of anticoagulant and depletion strategy, and storage
related problems. The most popular plasma peptide utilized4 International Journal of Alzheimer’s Disease
for biomarker research is Aβ, which is the fundamental
element of senile plaques in brain of AD patients [3]. Using
ELISA, Aβ can be detected in plasma. The ﬁndings from
diﬀerent studies have shown variable results. Some studies
have suggested slightly higher Aβ42 or Aβ40 plasma levels in
patients with AD than in controls [48]. However, most of the
studies have found no change in plasma Aβ concentration
between AD and healthy control [48]. It is also suggested
that large Aβ42/Aβ40 ratio could indicate the risk factors for
AD [49]. These ambiguous results are probably explained by
the fact that plasma Aβ is derived from peripheral tissues
and does not reﬂect brain Aβ production. Furthermore, the
h y d r o p h o b i cn a t u r eo fA β makes the peptide bind to plasma
proteins, which could result in “epitope masking” [16]
and other analytical interferences. Recently, analysis of 18
plasma signaling and inﬂammatory proteins has accurately
identiﬁed patients with AD and predicted the onset of AD
in individuals with MCI [50]. However, further studies are
required to analyze if this set of proteins is the best possible
recipe of plasma biomarkers for preclinical AD diagnosis.
4.Urine-BasedBiomarkers
Neural thread protein (NTP) levels have been consistently
identiﬁed as an AD biomarker in urine [51, 52]. With
disease severity, the urinary concentration of this protein
increases. AD associated NTP (AD7c-NTP) in CSF also
showed consistent results [51, 53]. More research needs
to be done to study the eﬀects of AD7c-NTP levels upon
therapeutic intervention [54–56]. Urinary F2-isoprostanes
have been reported to be increased [54–56] or unchanged
[57, 58], making them less reliable biomarkers. The utility
of urine sample for AD diagnosis has advantage that sample
collection is relatively easier and noninvasive compared to
CSF and plasma. However, very low protein concentrations
and high salt levels make it diﬃcult to use urine sample as a
source of biomarker [59].
5. CSFBiomarkers
Cerebrospinal ﬂuid (CSF) is a translucent bodily ﬂuid
that occupies the subarachnoid space and the ventricular
system around the brain. CSF acts as a “liquid cushion”
providing a basic mechanical and immunological protection
to the brain inside the skull and it can be obtained via
lumbar puncture. Although lumbar puncture is invasive
and potentially painful for the patient, CSF is probably
the most informative ﬂuid in biomarkers discovery for
neurodegenerative disease prognosis [10]. CSF has more
physical contact with brain than any other ﬂuids, as it is
not separated from the brain by tightly regulated blood
brain barrier (BBB). As a result, proteins or peptides that
may be directly reﬂective of brain speciﬁc activities as
well as disease pathology would most likely diﬀuse into
CSF than into any other bodily ﬂuid. These proteins and
metabolites can serve as excellent biomarkers of AD as well
as other neurodegenerative diseases. In early course of AD,
for an example of MCI, when the correct diagnosis is most
diﬃcult, CSF biomarkers would be valuable in particular
[10]. Tau and Aβ in CSF represents the earliest and most
intensively studied biomarkers [9, 10, 41, 60, 61]. Both
proteins are linked to hallmark lesions of AD, amyloid
plaques, and neuroﬁbrillary tangles. In the next section, we
willdiscusstheclinicalsigniﬁcanceofAβ andtaubiomarkers
in detail.
5.1. APP, Aβ40/42, and Truncated Aβ in CSF as Biomarkers.
One of the major pathological features of AD is the presence
of senile plaques primarily composed of Aβ,ap r o t e o l y t i c
fragment of the amyloid precursor protein (APP) (Figure 1)
[62]. The expression level of APP could serve as diagnostic
markers in AD [61]. However, the experimental studies of
APP expression level in CSF of AD patients are inconsistent
[61]. The inconsistencies between studies ruled out the
possibility of CSF-APP being a useful biomarker for AD.
APP is expressed in all tissues and could undergo cleavage
by either α-secretase or β-secretase to release sAPP-α or
sAPP-β, respectively. The processing of APP by α-secretase
occurs via nonamyloidogenic pathway, and a reduced CSF
level of sAPPα in AD patients has been reported [63]. In
contrast, APP processing ﬁrst by β-secretase and subsequent
digestion by γ-secretase leads to formation of Aβ (38–43
residues) peptides. The 42-residue-long Aβ isoform (Aβ42)
is highly hydrophobic and forms oligomers and ﬁbrils that
accumulate as extracellular plaques (Figure 1)[ 4]. Because
Aβ42 is the dominant component of the plaques seen in AD
[64], many groups have investigated the use of Aβ42, as well
as the other Aβ s p e c i e sa sad i a g n o s t i ct o o l .T h ea m o u n t
of total Aβ in CSF is not well correlated with the diagnosis
of AD [65]. The majority of studies have demonstrated a
decrease of CSF Aβ42 in AD patients [34, 66–70]. However,
fewreportssuggesttheincreased[71]orunchanged[72]CSF
Aβ42 in AD. These diﬀerences in observations might be due
to the variations in sample assaying protocols and selection
of patient groups. Deposition of the peptide in plaques
(“amyloid sinks”) is considered the underlying basis for the
decrease of CSF-Aβ42 levels seen in AD [36, 37]. Although
it is not clearly proved, the observation is supported by
the strong correlation between low CSF-Aβ42 levels and
high plaque burden when measured by PIB imaging [33].
This observation was further supported by the fact that AD
mouse model showed low CSF Aβ level with high amount
of plaque in the brain [73]. Although it has been shown that
CSF Aβ42 levels can identify PIB-positive individuals with
highest possible sensitivity and speciﬁcity, the decreased CSF
levels of Aβ42 have also been reported in other dementia
such as FTD [74–76]. Low concentrations of CSF Aβ42
was also found with individuals without PIB-positive plaque
[77]. This ﬁnding might be explained by the fact that PIB
binds ﬁbrillar Aβ not the Aβ oligomers or diﬀuse plaques
[77] that are found in earlier stages of AD process. It is
however that CSF Aβ4 2h a sh i g hp o t e n t i a la sab i o m a r k e r
for diagnosis, plaque burden, prognosis and may provide
clue of preclinical AD. Aβ40 is unchanged in the CSF
of AD patients [21]. However, the decreased Aβ42/Aβ40
ratio is much more pronounced in AD diagnosis than theInternational Journal of Alzheimer’s Disease 5
reduction of Aβ42 alone. Therefore, Aβ42/Aβ40 ratio might
be more useful in AD diagnosis in the early as well as the
clinical phases of the disease [78]. Moreover, the presence
of several shorter Aβ isoforms in CSF has suggested that Aβ
constitutesalargefamilyofpeptideswithconsiderablelength
variations. The carboxy-terminal truncated Aβ peptides
for example, Aβ37, Aβ38, and Aβ39 have been found in
CSF of AD subjects. In AD patients, an increase in Aβ38
levels, accompanied with a decrease in Aβ42 levels were
also observed [79, 80]. Thus, the Aβ42/Aβ38 ratio might
prove useful for more precise diagnosis of AD [79, 80].
Immunoprecipitation techniques and mass spectrometry
have identiﬁed a number of short truncated Aβ isoforms,
such as Aβ14, Aβ15, and Aβ16 in the CSF of AD patients.
These forms have been reported to be produced through
a novel pathway of APP processing involving the β and α
secretase actions [81]. In the AD subjects, elevated Aβ16
levels, accompanied with a decrease in Aβ42 levels were
reported in CSF [82].
5.2. CSF-Tau as a Biomarker. The protein tau is an intracel-
lular protein, which maintains the stability of microtubules
in neurons. In normal individual, only low concentration of
tau is present in CSF. The function of tau is tightly regulated
by a number of post-translational modiﬁcations including
phosphorylation at serine and threonine residues. The
precise form of tau in CSF and the mechanism for leakage of
intracellular tau into CSF is not clearly understood. Despite
intense research, the amyloid and tau pathologies remain
unclear. Several experimental studies have suggested that
hyperphosphorylation and NFT formation is the down-
stream phenomenon of AD pathologies [83]. However, it
is also noteworthy that loss of function of tau due to
hyperphosphorylation and subsequent detachment of tau
from microtubule could lead to the increased cytoskeleton
ﬂexibility and loss of axonal integrity in the brain (Figure 1)
[84]. In AD, tau becomes hyperphosphorylated and gets
dissociated from microtubule and subsequently polymerized
into insoluble paired helical ﬁlaments (PHF) [84]. PHF
eventually contributes to the formation of neuroﬁbrillary
tangles [85, 86]. NFT formation and neuronal degradation
is an essential part of AD pathology (Figure 1). Upon
signiﬁcant disruption of neuronal architecture, tau protein
couldbereleasedintoCSF[60].Therefore,increasedlevelsof
tau and hyperphosphorylated tau in CSF can correlate with
the onset of neurodegeneration in AD. The total tau (t-tau)
concentrationinCSFhasbeeninvestigatedbyELISAanalysis
usingmonoclonalantibodiesagainstalltauisoforms.Several
studies have suggested that t-tau concentration in CSF of
AD patients is higher than control [60, 87]. Although the
CSF t-tau is very sensitive biomarker for detecting AD, it
has limited ability to discriminate AD from other major
forms of dementia as t-tau also increased in CSF of others
form of dementia including vascular dementia (VAD) and
frontotemporal dementia (FTD) [60]. Several studies also
used the p-tau in CSF as potential biomarkers since it is
the major component of NFT. CSF concentrations of p-
tau in AD have been examined using ELISAs based on
monoclonal antibodies that can detect its various epitopes
of p-tau, namely, (Thr181 + Thr231), (Thr231 + Ser235),
Ser199, Thr231, (Ser396 + Ser404), and Thr181 [41, 88,
89]. ELISA study using all antibodies has showed increased
CSF concentration of p-tau in AD patients. Moreover,
the ability of increased p-tau assays to discriminate AD
from normal aging and other dementia is more sensitive
and speciﬁc than that of CSF concentrations of t-tau and
Aβ42 [60, 90, 91]. The experimental evidences of high
CSF concentrations of p-tau in only AD patients have
suggested that p-tau is not a simple marker of axonal
damage and neuronal degeneration, as t-tau, but it is more
closely related to AD pathology and the formation of
NFT.
5.3. Combined Aβ and Tau in CSF as Biomarkers. It has
been suggested that combinations of CSF markers could
more successfully discriminate AD from control or other
forms of dementia than an individual marker. There are
several studies where the diagnostic performance of the
combination of CSF t-tau and Aβ42 is analyzed. The
evidences have suggested that high CSF concentration of
t-tau and low concentrations of Aβ42 could detect AD
with high diagnostic sensitivity and speciﬁcity [61]. The
other combinations of CSF biomarkers have also been
evaluated, which suggested that the high CSF p-tau/Aβ42
ratio possesses higher sensitivity and speciﬁcity [18]f o r
diﬀerentiating AD from normal controls and from subjects
with other non-AD dementia than that of the CSF t-tau,
p-tau, Aβ42, and ratio of t-tau/Aβ42. It is also suggested
that the combination of tau and Aβ42 has more diagnostic
potential in terms of sensitivity and speciﬁcity in MCI
patients to develop future AD [92].
5.4. Oligomers of Aβ in CSF: Promising Biomarkers for
Early Diagnosis in AD. Recent studies have suggested that
oligomeric Aβs are the most neurotoxic species in AD. Sub-
stantial in vivo and in vitro evidence supports this hypothesis
[93–97]. Several in vitro neurotoxicity studies have shown
that Aβ oligomers are potent neurotoxins [98–104], and
the toxicity of some oligomers is higher than that of the
corresponding amyloid ﬁbrils [105]. The evidences, which
support the fact that Aβ oligomers could be targeted for drug
and biomarker discovery include (1) soluble oligomers could
inhibit hippocampal long-term potentiation (LTP) [95, 98,
100, 103, 104, 106, 107] and disrupt cognitive function [108]
in vivo; (2) compounds that bind and disrupt the formation
of oligomers have been shown to block the neurotoxicity
of Aβ [108, 109]; (3) drugs that reduce the amyloid plaque
burden without disruption of oligomers have little eﬀect
on recovery of neurological function [110]. Many oligomers
such as Aβ-derived diﬀusible ligand (ADDL)-like Aβ42
oligomers [111], 90kDa Aβ42 oligomer [112, 113], 56kDa
oligomer of “Aβ∗56 [114], and Aβ trimers [115] have shown
high in vivo toxicity, providing a compelling reason for Aβ
o l i g o m e r st ob eu s e da sp o t e n t i a lA Db i o m a r k e r se s p e c i a l l y
for early diagnosis in AD. In addition, elevated levels of6 International Journal of Alzheimer’s Disease
Aβ oligomers were detected in AD patients and transgenic
mice compared to control [116–118]. The elevated level
of oligomers could also appear in CSF but with lower
concentration. Therefore, highly sensitive techniques are
required for oligomer detection in CSF. The study using
ﬂuorescence correlation spectroscopy suggested the presence
of Aβ oligomers in CSF of AD patients, compared to
healthy control [119]. Recently, ultrasensitive, nanoparticle-
based, protein detection assay (bio-barcode) showed that
the ADDLs concentrations in CSF of AD patients were
consistently higher than the nondemented age-matched
control [120]. In this study, ADDLs speciﬁc antibodies
coupled to DNA-tagged nanoparticles were used to capture
the oligomers from the CSF of patients with AD. Although
the number of AD patients and controls studied was low,
theﬁndingswereverypromising.AlthoughAβ oligomersare
attractive biomarker candidates, several limitations exist to
use these species. The concentration of these Aβ oligomers
in CSF is very low in comparison with Aβ monomers.
Again, the detection of individual Aβ oligomers is diﬃcult
since oligomers are metastable and therefore one form of
oligomers could transform to another form immediately.
Assay sensitivity must reach very high level if one can detect
total heterogeneous population of Aβ oligomers in CSF.
The monoclonal antibodies speciﬁc for only Aβ oligomers
could be diﬃcult to develop. Recently, an antibody against
Aβ oligomers was developed, which can detect all Aβ
oligomers, including oligomers from other amyloidogenic
protein [117]. However, using these oligomers speciﬁc
a n t i b o d yt od i a g n o s eo fA Di sd i ﬃcult since it cannot
diﬀerentiateADfromotherneurodegenerativediseases.New
analytical methods and novel oligomers-speciﬁc antibody
mustbedevelopedtodetectoligomersinCSFofADpatients,
which would have ultimate ability to detect early onset of
AD.
5.5. Neuronal Biomarkers in CSF. Besides tau and Aβ,
neuronal and synaptic proteins could also be used as CSF
biomarkers in AD. For example, Visinin-like protein 1 (VLP-
1), a calcium sensor protein was shown to be signiﬁcantly
increased in the CSF of AD subjects compared to controls.
It is believed to seep out from dented neurons [121].
The sensitivity and speciﬁcity of CSF VLP-1 is comparable
to CSF t-tau, p-tau, and Aβ42. Combined analysis of
Aβ42, p-tau, and VLP-1 has been reported to raise the
diagnostic precision of AD. VLP-1 biomarker might also
prove useful in indicating the degree of dementia [121]. The
neuroﬁlaments, which are structural component of axons,
could also be used as biomarkers for discriminating AD
patients from other forms of dementia, as their expression
levels are high in VAD and FTD [122], while normal
levels are found in most AD patients. Another synaptic
protein called growth-associated protein (GAP-43) is found
in higher levels in CSF of AD than that of controls, and
FTD [123]. Furthermore, it has been shown that CSF GAP-
43 and t-tau were increased in AD and correlated positively
[123], suggesting both biomarkers are reﬂecting axonal and
synaptic degeneration.
5.6. Oxidative Stress Marker in CSF. Besides the formation
of amyloid plaque and NFT, AD is also frequently charac-
terized by reactive oxygen species (ROS)-mediated neuronal
damage. The oxidative damage in the brain mainly involves
lipid peroxidation [124]. Polyunsaturated fatty acids are sus-
ceptible to oxidation by reactive oxygen species. Isoprostanes
are lipid oxidation products generated due to the reaction
between fatty acids and ROS. Therefore, isoprostanes could
be used as valuable AD biomarkers. Several studies have
suggested that F2-isoprostanes, a group of isoprostanes,
are increased in CSF of AD patients compared to healthy
control or patients with other dementia [125, 126]. CSF-
F2-isoprostanes have also been shown to be increased in
patients with MCI and asymptomatic carriers of familial AD
mutations. A combined analysis of CSF-Aβ42, tau, and F2-
isoprostanes, was able to diagnose AD with a sensitivity of
84% and speciﬁcity of 89% [127].
5.7.InﬂammatoryBiomarkersinCSF. ADpathologyinvolves
release of inﬂammatory mediators. The diﬀerential occur-
rence of several proteins due to inﬂammatory process in
AD might be used as biomarker. These proteins can be
detected using ELISA, as well as proteomics approaches.
One of the most studied inﬂammatory biomarkers is
α1-antichymotrypsin (A1ACT), which is observed either
increased [45, 128] or unchanged [129] in CSF samples
of AD patients. However, the contradictory results suggest
that more studies must be conducted to raise the possibility
of A1ACT to be regarded as an eﬀective biomarker. The
study of cytokines, which are produced during inﬂam-
mation processes in AD, also gave inconsistent results.
For example, CSF interleukin-6 (IL-6) levels have been
reported to be increased [130–132], decreased [133], or
unchanged [134–136]i nA D .S t u d i e so fI L - 6r e c e p t o r ,
Gp130, and tumor necrosis factor (TNF-α) also produced
conﬂicting results [137]. The genetic background, envi-
ronmental factors, and usage of anti-inﬂammatory drugs
might produce substantial variation in cytokine levels in an
individual [138]. This could be the reason for such uncertain
results.
6. CSFBiomarkers:
A PotentialHope for AD Diagnosis
As discussed in the preceding sections, most biomarker
research in AD is based on either brain imaging or is
ﬂuid-based. Although imaging techniques are deﬁnitive tests
for detecting amyloid plaques and atrophy using molecular
probe, still antemortem diagnosis of AD and MCI are
less successful. More sensitive chemical probes are required
to be developed, which would bind oligomers or diﬀuse
plaque. However, imaging techniques being very expensive
and requiring more experience for handling the instruments
precludes their day-to-day use for AD diagnosis. In ﬂuid
biomarker research, CSF has been proved to be a supreme
source for biomarkers for several reasons. CSF is in close
proximity to the brain, and therefore biochemical changes in
the brain aﬀect the composition of biomarkers in CSF. SinceInternational Journal of Alzheimer’s Disease 7
AD pathology is restricted to the brain, CSF is an obvious
source of biomarkers for AD. CSF is also a rich source
of brain-speciﬁc proteins, and changes in these protein
levels are observed in CSF with disease progression. CSF
biomarkers are also very sensitive to the ﬁne changes in brain
that occur in the preclinical stages of the AD. Therefore,
CSF is probably the most informative ﬂuid sample available
for preclinical as well as symptomatic AD diagnosis. The
diagnostic sensitivity and speciﬁcity of CSF biomarkers in
diﬀerentiating AD from healthy controls, and from other
formsofdementiaisalreadyachievedwithsatisfactorylevels.
Moreover, a combination of more than one biomarker in
CSF, such as CSF p-tau, t-tau, and Aβ42 is considered
to give higher diagnostic accuracy of AD. It can identify
AD, prodromal AD, and also can diﬀerentiate AD from
other dementia with high sensitivity and speciﬁcity that is
otherwise impossible to achieve.
Although CSF biomarkers have proved to be highly
informative, sensitive, and speciﬁc for detection of clinical
AD and early stage of AD, their regular use in clinic is
still limited. One of the major reasons against the vast
applicability of CSF in AD diagnosis is lumbar puncture,
an invasive method to collect the CSF sample. Other issues
includinginconsistencyofdataanalysisofCSFsampledueto
sample collection, transportation, storage, and high expense
of the test might limit the use of CSF for routine diagnosis.
However, various strategies are available to resolve these
issues. For example, the Clinical Neurochemistry Laboratory
in Gothenburg, Sweden and Alzheimer’s Association, have
together started a quality control program, the objective
of which is to standardize CSF biomarker measurements
between both research and clinical laboratories [10]. This
program would obviously enhance the diagnostic precision
of CSF markers, thus enabling them to support a routine
analysis for diagnosis of AD.
7. FutureDirection
According to the current clinical diagnostic criteria, AD
diagnosis cannot be made until the patient has dementia,
which is deﬁned as cognitive symptoms severe enough to
interfere with social or occupational activities [139]. This
might hinder the preclinical diagnosis of AD. The disease
modifying drugs will be most eﬀective and will have most
therapeutic value if these are administered in the earliest
stage of AD, before amyloid plaques and NFT become preva-
lent. Since AD is a multifactorial neurodegenerative disorder
both at clinical and neuropathological level, development of
biomarkers with 100% eﬃciency in terms of sensitivity and
speciﬁcity is diﬃcult to achieve. Also, the eﬀectiveness of
the disease modifying drugs could vary from one subgroup
to another subgroups, making the utility of biomarkers in
clinical trial and drug discovery diﬃcult. Combined analysis
of CSF biomarkers represents more suitable diagnostic tool
to detect AD patients or detect individuals with MCI.
Moreover, sensitive assays should be developed to detect
amyloid oligomers in CSF and in the brain. This would raise
the possibility for the diagnosis of early onset of AD.
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